Dalbavancin hydrochloride

Dalbavancin hydrochloride Chemische Eigenschaften,Einsatz,Produktion Methoden

• Biologische Aktivität

  Dalbavancin hydrochloride(MDL-63397 hydrochloride) is a semi-synthetic lipoglycopeptide antibiotic with potent bactericidal activity against Gram-positive bacteria. Dalbavancin hydrochloride inhibits Staphylococcus aureus and Bacillus anthracis with MIC90 of 0.06 μg/mL and 0.25 μg/mL, respectively.

• in vitro

  Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA ), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci , organisms against which it has shown greater potency than existing glycopeptide therapeutic agents.

• in vivo

  Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens.

  Animal Model:	Female BALB/c mice (6-8 weeks) challenged with Ames strain of B . anthracis
  Dosage:	15 mg/kg, 30 mg/kg, 60 mg/kg, 120 mg/kg, 240 mg/kg
  Administration:	Intraperitoneal injection ; every 36 h or 72 h; for 14 days
  Result:	The efficacy was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg/kg every 36 h or 30 to 240 mg/kg every 72 h.

Dalbavancin hydrochloride Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(43)Suppliers